A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects

NCT04651036 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: QL0605
DRUG: US Neulasta

Sponsor

Qilu Pharmaceutical Co., Ltd.